15. MOLECULAR MECHANISMS IN ALZHEIMER'S DISEASE

by Ana Stavljenic – Rukavina
Zagreb University School of Medicine,
Clinical Institute of Laboratory Diagnosis
Zagreb Clinical Hospital Center, School of Medicine,
University of Zagreb,
Kišpaticeva 12, 10 000 Zagreb Croatia

15.1 Introduction

Alzheimer's disease (AD), a progressive neurovegetative disorder of the central nervous system and a leading cause of dementia, is partially caused by genetic changes.

The molecular mechanisms and hypothesis of AD is very complex. The key event leading to AD appears to be the formation of a peptide known as amyloid beta (Aβ) which clusters into amyloid plaques or senile plaque on blood vessels and on the outside surface of neurons of the brain, which ultimately leads to the killing of neuron. Amyloid cascade of events in AD would be:

Aβ formation → amyloid plaques → neuron death → dementia

The amyloid β-peptide is created by enzyme clipping of the neuron membrane protein known as amyloid precursor protein (APP). Enzymes can clip APP in the ways that do not result in amyloid β formation. Moreover, there are two forms of amyloid β-peptide, one with 40 and other with 42 aminoacids. The 42 amino acid peptide is more hydrophobic than that with 40. Following amyloid plaque formation, two processes play an important role in causing the death of neurons; inflammation and neurofibrillary tangles. Two major types of brain cells that participate in immune and inflammatory process are astrocytes and microglia. The number of astrocytes seems to be enlarged in AD and activated to produce prostaglandin leading to arachidonic acid mediated inflammation. Furthermore, activated microglial cells produce free radicals and this mechanism leads to the death of neurons.

Neurons can be very large and nutrient substances as well as cell regulation components are transported along microtubules. Structural integrity of microtubules is maintained by tau protein. In AD, tau protein loses its capacity to bind to microtubules but binds to each other forming paired helical filaments forming knots known as neurofibrillary tangles (NFTs) which further cause microtubule death.

With these facts in mind, the second part of the amyloid cascade would be:

APP → Aβ42 → amyloid plaque → inflammation NFTs → neuron death.

The formation of Aβ42 from APP is regulated by secretases – two enzymes that compete to cleave APP and consequently cause formation of insoluble amyloid plaques. α-secretase cleaves APP in a way in which Aβ42 is not formed. On the contrary, β-secretase and, in the next step, γ-secretase cleaves APP forming either 40 aminoacid amyloid protein which is soluble, or 42 aminoacid amyloid peptide which clumps together forming insoluble amyloid plaques.

15.2 Genetics of AD

Familial AD is genetically heterogeneous and appears in two forms: early-onset FAD and late-onset FAD. FAD accounts for only 10% of all AD occurring between 30 and 60 years of age. Mutations in three genes, i.e. coding amyloid β-precursor protein (APP), presenilin-1 (PS-1) and presenilin-2 (PS-2) have been found in FAD.

| GENE             | CHROMOSOME | PROTEIN |
|------------------|------------|---------|
| Presenilin-1     | 14         | $\text{S}182$ |
| Presenilin-2     | 1          | $\text{STM}2$ |
| Amyloid Precursor Protein | 21       | $\text{Aβ}$ |
| Apo-4ipoprotein E | 19        | $\text{APOE}$ |

Furthermore, it has been shown that mutations in those genes leads to elevated levels of amyloid β (Aβ44), a proteolytic fragment of APP found in a deposited form in the brain of FAD. Not all cases of early-onset FAD are accounted for by APP, PS-1 and PS-2 mutations, so it is likely that other genes remain to be identified.
Figure 2. Ideograms of human chromosomes 1, 14, 19 and 21 showing cytogenetic locations of genes presenilin, presenilin 1, apolipoprotein E and amyloid ß-precursor protein h

Apolipoprotein (ApoE) gene polymorphism was studied as a potential major susceptibility factor for late-onset AD. ApoE is a glycoprotein involved in cholesterol transport and the metabolism of lipoprotein particles. The polymorphic form of ApoE allele e4 has been studied in multi-national study ApoE Europe in which a Croatian group had taken a significant part. The results of our study support the role of ApoE 4 in AD patients. ApoE binds avidly to synthetic and soluble bA4 peptide in CSF. ApoE4 does not bind to tau protein in vitro unlike E2 and E3. It seems that interaction between ApoE3 and tau protein serves as protection against tau phosphorylation and tangle formation. This protein was supposed to have an additional role in other neurovegetative disorders regulating to some extent cholinergic metabolism in human brain that may have an impact on neuronal plasticity and regenerative capacity in brain.

15.3 Apo E allele frequency in Croatian AD patients

|   |   |   |   |
|---|---|---|---|
|   | t2 | t3 | t4 | OR (C/T) p |
| Case (87) | 29 | 23.5 | 44.8 | 13.96 <0.001 |
| Control (88) | 28 | 91.1 | 7.4 | 6.48-30.08 |

In some other studies, it has been found that a-1-antichimotripsin (ACT) and PS-1 (intron 8 polymorphism) modify the risk associated with the ApoE 4 allele to induce AD. To establish the specific role of ApoE in AD, it is essential to determine the extent of association of e4 allele with types of dementia other than AD.

The USA National Institute on Aging and the Alzheimer Association regard ApoE genotyping as an adjunctive test for AD, since patients with AD are more likely to have an ApoA allele than patients with other forms of dementia. However, it is not clear from other studies whether the ApoE4 allele is more strongly associated with AD than with other types of dementia.

There is increasing evidence for the role of ApoE in the pathogenesis of AD. ApoE is detectable by immunohistochemistry in senile plaques, neurofibrillary tangles and cerebrovascular amyloid in AD brain. The distinctive binding properties of ApoE isoforms to bA4 peptide and tau protein have suggested ways in which ApoE might mediate its action.

The APP gene is located on chromosome 21 and a total of six missense mutations have been described so far. All of them were shown to be connected with AD, but about 2% of all published cases of FAD and 5-20% of early-onset FAD have one of these mutations. At least 41 different mutations have been found in PS gene that is located on chromosome 14. Almost all mutations were found in AD patients and PS-1 mutations account for 30-50% of AD families. PS-2 gene mutations (chromosome 1) account only for 2% of all early-onset FAD.

Figure 3. Domain structure of APP showing the position of mutations causing Alzheimer’s disease within amyloid b (bA4) and secretase cleavage sites.

Table 2. APP mutations associated with AD

| Number of families | Mean age of onset | Mutation |
|--------------------|------------------|----------|
| 1                  | 692              | Hsukishi et al., 1992 |
| 2                  | 650              | Mullin et al., 1992 |
| 3                  | 670              | Abn Mat 671 |
| 4                  | 717              | Bica et al., 1997 |
| 5                  | 717              | Matsushita et al., 1991 |
| 6                  | 717              | Moll et al., 1991 |
| 7                  | 717              | Chau et al., 1991 |
| 8                  | 717              | Gourley et al., 1996 |
| 9                  | 717              | Zlokas et al., 1992 |
| 10                 | 717              | Sorens et al., 1999 |
| 11                 | 717              | Sorens et al., 1999 |
| 12                 | 717              | Matsunuma et al., 1996 |
| 13                 | 717              | Campion et al., 1996 |

15.4 How do these mutations impact APP function?

The APP mutation at codon 693 may alter the secondary structure of bA4 peptide in cell membrane resulting in premature deposition. Mutations at codons 670/671 and 717 do not lie within bA4 but flank it, lying very close to sites of secretase cleavage. Soluble form of bA4 (1-40) peptide is rapidly cleared preventing plaque formation in the brain. Longer peptides of 42-44 aminoacids aggregate more rapidly into fibrils. The APP 717 mutations produced up to two times longer and a more insoluble form of APP.
that aggregates rapidly and promotes peptide deposition, and APP 692 mutation leads to formation of an APP molecule containing truncated E4 peptide, which is at the same time overproduced.

Since most early-onset AD families do not have mutations in the APP gene, it was expected that other AD loci might exist. In 1992, many investigators have shown that a second locus: S18, PS-1, AD3 on chromosome 14 may be responsible for the early-onset FAD.

PS-1 gene contains 10 protein-coding exons and 2 or 3 additional exons encoding the 5'-untranslated protein. PS-1 gene undergoes alternate splicing as well as inclusion or exclusion of codons 26-29 at 3' end. At least 41 different FAD mutations in PS gene have been identified in more than 50 unrelated families, most of them in exon 5 and 8. The known FAD mutations are distributed through PS-1 gene, most of them in predicted TM domains. Furthermore, all FAD missense mutations occur in aminoacids that are conserved in PS-1 and PS-2.

Presenilin-2 gene (PS-2) was found and isolated based on its homology to the PS-1 gene. It contains 10 protein-coding exons and two additional exons encoding the 5'-untranslated region. The PS-2 isoform missing exon 8 has been described. Evidence for specificity of function for both presenilins derives from the presence of non-homologous regions in molecules. The mean age of onset in FAD families with PS-1 gene mutation is earlier (44 years) than in families with PS-2 gene mutations (mean: 50 years).

### 15.5 Other factors

Additional genetic factors may be involved in the manifestation of the AD disease. a1-antichymotrypsin (ACT) protein levels in plasma and CSF have been observed to be elevated in AD patients, and therefore ACT has been proposed as a biochemical marker for AD. ACT is intimately associated functionally within the bA4 peptide in AD brains and ACT appears to promote fibril formation of the bA4 peptide, and thus the deposition of amyloid ACT protein belongs to the class of serine proteinase inhibitors (serpins) and is encoded by a gene on chromosome 14.

A polymorphism has been described in the signal peptide sequence of ACT with nearly equal frequencies in the general population. This biallelic polymorphism of the ACT gene has been described to cause an amino acid exchange Ala (A) to Thr (T) at codon 15 in the signal peptide region and has been stated to confer a significant risk for AD.

Patients with the combination of ACT/AA phenotype and ApoE e4 allele were reported to have a two- to three-fold increased risk for AD.

Some investigators suggest that the degenerative changes in AD are preceded by vascular or atherogenic changes that reduce blood flow and thereby induce ischemic and oxidative stresses leading to AD.

## References

1. Brooks WS, Martins RN, DeVoecht J, Nicholson GA, Schofield PR, Kwok JB, Fisher C, Yeung LU, van Broeckhoven C. A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer’s disease. Neurosci Lett 1995; 199:183-6.

2. Campion D, Brice A, Hannequin D, Charbonnier F, Dubois B, Martin C, Michon A, Penet C, Bells M, Calenda A, Martinez M, Agid Y, Clerget-Darpoux F, Fieux T, the French Alzheimer’s disease study group: No founder effect in three novel Alzheimer’s disease families with APP 717 Val-Ile mutation. J Med Genet 1996;33:661-4.

3. Chartier-Harlin MC, Crawford F, Houldon H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy P, Mullan M. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the b-amyloid precursor protein gene. Nature 1991;353:844-6.

4. Cruts M, Hendriks L, Van Broeckhoven C. The presenilin genes: a new gene family involved in Alzheimer’s disease pathology. Hum Mol Genet 1996;5:1449-55.

5. Fidani L, Goate A. Mutations in APP and their role in beta-amyloid deposition. Prog Clin Biol Res 1992;379:195-214.

6. Gassenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 1984;120:885-90.

7. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Guffria L, Haynes A, Irving N, James L, Mant R, Newton P, Ronke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991;349:704-6.

8. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997;20:134-9.

9. Heilisalmi S. Molecular genetics of Alzheimer’s disease with special emphasis on presenilin, amyloid beta precursor protein and apolipoprotein E genes. Series of Reports, Department of Neurology, University of Kuopio, 1997;44.

10. Hendriks L, van Duijn CM, Cras P, Cruts M, van Hal W, van Harsskamp F, Warren A, Mclnnes MG, Antonarakis SE, Martin JJ, Hofman A, van Broeckhoven C. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the b-amyloid precursor protein gene. Nature Genet 1992;1:218-21.

11. Hutton M and Hardy J. The presenilins and Alzheimer’s disease. Hum Mol Genet 1997;6:1639-46.

12. Karlinsky H, Vaula G, Haines JL, Ridgley J, Bergeron C, Mortilla M, Tulpier RG, Percy M, Rohitaille Y, Noldy NE, Yip TCK, Tanzi RE, Gusella JF, Becker R, Berg JM, McLachlan DRC, St George-Hyslop PH. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer’s disease and a missense mutation in codon 717 of the b-amyloid precursor protein gene. Neurology 1992;42:1445-53.

13. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer’s disease using molecular genetics. JAMA 1997a;277:825-31.

14. Levy-Lahad E, Wasco W, Poonkaj P, Romano DM, Oshima J, Pettigrew WH, Yu C, Jonord FD, Schmidt SD, Wang K, Crowley AC, Fu Y, Hu, Guenette Sy, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE. Candidate gene for chromosome 1 familial Alzheimer’s disease locus. Science 1993b;260:973-7.

15. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KAB, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer’s disease locus on chromosome 1. Science 1995c;269:970-3.

16. Mann D: The pathological association between Down syndrome and Alzheimer’s disease. Mech Age Dev 1995; 43:99-136.
17. Matsumura Y, Kitamura E, Miyoshi K, Yamamoto Y, Furuyama J, Sugihara T: Japanese siblings with missense mutation (717Val®Ile) in amyloid precursor protein of early-onset Alzheimer’s disease. Neurology 1996;46:1721-5.

18. Mullan M, Crawford F, Axelman K, Houilden H, Lilias L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of b-amyloid. Nature Genet 1992;1:345-7.

19. Murrell J, Farlow M, Ghetti B, Renson MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 1991;254:59-7.

20. Naruse S, Igarashi S, Aoki K, Kaneko K, Iihara K, Miyatake T, Kobayashi H, Imaizumi T, Shimizu T, Kojima T, Tsujii S: Missense mutation Val®Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer’s disease. Lancet 1991;337:576-8.

21. Pirrtala T, Lehtimäki T, Rinne J, Mattila K, Frey H, Nikkari T. The frequency of apolipoprotein E4 allele is not increased in patients with probable vascular dementia. Acta Neurol Scand 1996a; 93:352-4.

22. Poirier J, Delisle M-L, Quirion R, Aubert I, Farlow M, Lahiri D, Hsu S, Bertrand P, Nalbantoglu J, Gillis BM, Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260-4.

23. Salzer B, Stavlienic A, Jurgens G, Duncic M, Radica A. Polymorphism of apolipoprotein E, lipoprotein (a) and other lipoproteins in children with type I diabetes. Clin Chem 1993; 39:7:1427-32.

24. Selkoe DJ, Polinsky MB, Joachim CL, Vickers EA, Lee G, Fritz LC, Oltersdorf T. b-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci 1988;85:7341-5.

25. Sherrington R, Rogan E, Liang Y, Rogasen EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar I, Foncins J-F, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pissini L, Nee L, Chumakov I, Pellen D, Brooks A, Sanseau P, Polinsky RJ, Wasco W, D'Ha SA, Haines JL, Pericak-Vance MA, Tanzi RE, Roses RA, Shalat S, Soininen H, Hofman A, for the Eurodementia study group: Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991a; 20(Suppl 2):S13-S20.

26. Wisniewski KE, Dalton AJ, Crapper-McLachlan DR, Wen GY, Wisniewski HM. Alzheimer’s disease in Down’s syndrome: clinicopathologic studies. Neurology 1985;35:957-61.

27. Wragg M, Hutton M, Tallbot C, the Alzheimer’s disease collaborative group: Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer’s disease. Lancet 1996;348:509-12.

28. Yoshikawa K, Miki T, Katsuya T, Oghara T, Sakaki Y. The 717Val®Ile substitution in amyloid precursor protein is associated with familial Alzheimer’s disease regardless of ethnic groups. Biochem Biophys Res Commun 1991;178:1141-6.

29. Yoshizawa T, Komatsuzaki Y, Iwamoto H, Mizusawa H, Kanazawa T. Screening of the missense mutation producing the 717Val®Ile substitution in the amyloid precursor protein in Japanese familial and sporadic Alzheimer’s disease. J Neurol Sci 1993;117:12-5.